EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterisation of tyrosine kinase inhibitor-receptor interactions at VEGFR2 using sunitinib-red and nanoBRET

Marieke Van Daele, Laura E Kilpatrick, Jeanette Woolard, Stephen J Hill

Biochemical Pharmacology · 2023

DOI: 10.1016/j.bcp.2023.115672 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2023. Verfasst von Marieke Van Daele und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham NG7 2UH, UK; Centre of Membrane …. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor A, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, University of Nottingham, H2020 Marie Skłodowska-Curie Actions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vascular endothelial growth factor (VEGF) is an important mediator of angiogenesis, proliferation and migration of vascular endothelial cells. It is well known that cardiovascular safety liability for a wide range of small molecule tyrosine kinase inhibitors (TKIs) can result from interference with the VEGFR2 signalling system. In this study we have developed a ligand-binding assay using a fluorescent analogue of sunitinib (sunitinib-red) and full length VEGFR2 tagged on its C-terminus with the bioluminescent protein nanoluciferase to monitor ligand-binding to VEGFR2 using bioluminescence resonance energy transfer (BRET). This NanoBRET assay is a proximity-based assay (requiring the fluorescent and bioluminescent components to be within 10 nm of each other) that can monitor the binding of ligands to the kinase domain of VEGFR2. Sunitinib-red was not membrane permeable but was able to monitor the binding affinity and kinetics of a range of TKIs in cell lysates. Kinetic studies showed that sunitinib-red bound rapidly to VEGFR2 at 25 °C and that cediranib had slower binding kinetics with an average residence time of 111 min. Comparison between the log Ki values for inhibition of binding of sunitinib-red and log IC50 values for attenuation of VEGF165a-stimulated NFAT responses showed very similar values for compounds that inhibited sunitinib-red binding. However, two compounds that failed to inhibit sunitinib-red binding (dasatinib and entospletinib) were still able to attenuate VEGFR2-mediated NFAT signalling through inhibition of downstream signalling events. These results suggest that these compounds may still exhibit cardiovascular liabilities as a result of interference with downstream VEGFR2 signalling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor ATyrosine Kinase InhibitorsSunitinibEndothelial CellsLigandsKineticsProtein Kinase InhibitorsVascular Endothelial Growth Factor Receptor-2

Stichwörter der Autor:innen

Ligand-bindingNFATNanoBRETSunitinib-redTyrosine kinase inhibitorsVEGFR2

Substanzen

SunitinibVascular Endothelial Growth Factor ATyrosine Kinase InhibitorsLigandsProtein Kinase InhibitorsVascular Endothelial Growth Factor Receptor-2

Autor:innen und Institutionen

  • Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham NG7 2UH, UK; Centre of Membrane Proteins and Receptors, University of Birmingham and Nottingham, The M…
  • Centre of Membrane Proteins and Receptors, University of Birmingham and Nottingham, The Midlands, UK; Division of Bimolecular Science and Medicinal Chemistry, School of Pharmacy, Biodiscovery Institute, University of No…

Förderung

  • Medical Research Council
  • University of Nottingham
  • H2020 Marie Skłodowska-Curie Actions
  • European Union

Zitieren

APA

Van Daele, M., Kilpatrick, L. E., Woolard, J., & Hill, S. J. (2023). Characterisation of tyrosine kinase inhibitor-receptor interactions at VEGFR2 using sunitinib-red and nanoBRET. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2023.115672

Vancouver

Van Daele M, Kilpatrick LE, Woolard J, Hill SJ. Characterisation of tyrosine kinase inhibitor-receptor interactions at VEGFR2 using sunitinib-red and nanoBRET. Biochemical Pharmacology. 2023. doi:10.1016/j.bcp.2023.115672

BibTeX
@article{VanDaele2023,
  author = {Van Daele, Marieke and Kilpatrick, Laura E and Woolard, Jeanette and Hill, Stephen J},
  title = {Characterisation of tyrosine kinase inhibitor-receptor interactions at VEGFR2 using sunitinib-red and nanoBRET},
  journal = {Biochemical Pharmacology},
  year = {2023},
  doi = {10.1016/j.bcp.2023.115672}
}
Kostenlos starten →